Valent
Valent is valsartan 80/160 mg tablets — ARB covering the starter-to-maintenance dose range. For hypertension (start 80 mg; titrate to 160 mg; max 320 mg once daily), heart failure with reduced ejection fraction (Val-HeFT target 160 mg twice daily), and post-MI left-ventricular dysfunction (VALIANT non-inferior to captopril).
✓ Medisch beoordeeld door Morgan Ellis — Apotheekonderzoeker · 8 jaar ervaring · Laatst beoordeeld: mei 2026
⚡ Quick Answer — What is Valent?
Valent is een 80 / 160 mg valsartan tablet from a WHO-GMP certified manufacturer — an angiotensin II receptor blocker (ARB). ARBs are first-line antihypertensive therapy alongside ACE inhibitors, CCBs, and thiazides per NICE, AHA/ACC, and ESC/ESH guidelines — and are the preferred alternative when an ACE inhibitor is not tolerated (usually because of the dry cough, which affects up to 20% of ACE-inhibitor users). Introduced 1996 (Novartis as Diovan). The ARB with the most heart-failure evidence after losartan; component of the sacubitril/valsartan combination (Entresto) that replaced ACE inhibitors as first-line HF-REF therapy in the 2021 ESC guidelines. Active drug (not a prodrug); no metabolic activation. Half-life 6 hours but effect lasts 24 hours via tight AT1 receptor binding. Typical hypertension dose: start 80 mg once daily (40 mg in elderly, volume-depleted, or hepatic impairment), target 160 mg once daily. Component of sacubitril/valsartan (Entresto) — the angiotensin receptor-neprilysin inhibitor (ARNI) class. PARADIGM-HF trial (2014) showed sacubitril/valsartan reduced cardiovascular mortality by 20% vs enalapril in HF-REF, changing first-line HF-REF therapy. Standard valsartan monotherapy remains an option in patients unable to afford or tolerate sacubitril/valsartan. Absolutely contraindicated in pregnancy (all trimesters — same teratogenic profile as ACE inhibitors: fetal renal agenesis, oligohydramnios, pulmonary hypoplasia), bilateral renal artery stenosis, and concurrent sacubitril/valsartan or aliskiren. Monitor potassium and creatinine.
📦 Elke bestelling is gedekt door onze Reshipment Assurance Policy — als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.
Waarom bestellen bij MedsBase
Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen — geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor — nooit “MedsBase” of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.
What Is Valent?
Valent is an oral 80 / 160 mg valsartan tablet from a WHO-GMP certified manufacturer, supplied in 30-180 tablets. Introduced 1996 (Novartis as Diovan). The ARB with the most heart-failure evidence after losartan; component of the sacubitril/valsartan combination (Entresto) that replaced ACE inhibitors as first-line HF-REF therapy in the 2021 ESC guidelines. Active drug (not a prodrug); no metabolic activation. Half-life 6 hours but effect lasts 24 hours via tight AT1 receptor binding.
How Valsartan Lowers Blood Pressure
ARBs block the angiotensin II type 1 (AT1) receptor directly, preventing angiotensin II from binding and exerting its vasoconstrictor and aldosterone-releasing effects. This is one receptor downstream of where ACE inhibitors act (which block angiotensin II formation) and produces equivalent clinical effects:
- Direct arterial vasodilation — lower systemic vascular resistance = lower blood pressure
- Reduced aldosterone secretion — less sodium and water retention
- Reduced sympathetic nervous system activation
- Improved endothelial function and reduced ventricular remodelling — the vascular-protective mechanism beyond simple BP lowering
- NO bradykinin accumulation — this is the key clinical difference from ACE inhibitors. ARBs do NOT cause the dry cough that affects up to 20% of ACEi users, because they don’t interfere with bradykinin metabolism.
Clinical consequence of this mechanism: ARBs achieve equivalent BP control to ACE inhibitors with lower rates of cough (0-3% vs 20% for ACEi) and angioedema (roughly 30-50% lower than ACEi, though not zero).
Approved and Evidence-Based Uses
- Hypertension — primary indication; first-line per international guidelines
- Heart failure with reduced ejection fraction (HF-REF) — Val-HeFT evidence; precursor to ARNI
- Post-myocardial infarction left-ventricular dysfunction — VALIANT
- Hypertension (wide dose range allows titration from 40 mg to 320 mg)
- Intolerance to ACE inhibitors (cough, less commonly angioedema) — standard switch target
Pivotal trial evidence: Val-HeFT (2001) — valsartan in HF-REF reduced hospitalisation. VALIANT (2003) — valsartan non-inferior to captopril in post-MI left-ventricular dysfunction. VALUE (2004) — valsartan vs amlodipine in high-risk hypertension; slight advantage to amlodipine on stroke + MI endpoints, driven largely by more rapid BP control with amlodipine.
Valent Dosage
Hypertension:
- Starting dose: 80 mg once daily (40 mg in elderly, volume-depleted, or hepatic impairment)
- Target dose: 160 mg once daily
- Maximum: 320 mg once daily
- Titrate every 2-4 weeks; full antihypertensive effect at 3-6 weeks
Heart failure: 40 mg twice daily, titrate to 160 mg twice daily (Val-HeFT target)
Administration: once daily, with or without food. Take at the same time each day for stable BP control.
Monitoring:
- Baseline: urea, electrolytes (particularly potassium), creatinine, eGFR. Home BP baseline.
- After 1-2 weeks: repeat U&E. Small rise in creatinine (up to 30%) is expected and acceptable. Small rise in potassium is common.
- After dose increase: repeat U&E at 1-2 weeks.
- Ongoing: annual U&E once stable.
- Stop and investigate: creatinine rise >30%, eGFR fall >25%, potassium >5.5, symptomatic hypotension.
Discontinuation: no withdrawal syndrome; however, abrupt stop causes BP rebound over days. Taper over 1-2 weeks when stopping.
Bijwerkingen
Common (>1%, usually mild):
- Dizziness, postural hypotension (usually mild; more common at start of therapy)
- Mild hyperkalaemia
- Expected small creatinine rise (up to ~30% is acceptable; intrarenal haemodynamic change, not nephrotoxicity)
- Fatigue, headache
- Upper respiratory symptoms, nasopharyngitis
- Back pain, muscle cramps
Uncommon but important:
- Angioedema — lower rate than with ACE inhibitors but still possible. Incidence ~0.1%. Do NOT use an ARB if the patient has a documented history of angioedema to an ACE inhibitor in the first 4 weeks; longer-term cautious use often acceptable.
- Severe hyperkalaemia — particularly with potassium-sparing diuretics (spironolactone), potassium supplements, NSAIDs, or CKD
- Acute kidney injury in bilateral renal artery stenosis — same mechanism as ACE inhibitors
- First-dose hypotension in volume-depleted patients (e.g. on high-dose diuretics, severe HF)
Contra-indicaties
- Pregnancy — ABSOLUTE contraindication at all trimesters. Same teratogenic profile as ACE inhibitors. Stop immediately on pregnancy; switch to labetalol, methyldopa, nifedipine, or hydralazine.
- History of angioedema with any ACE inhibitor or ARB (within 4 weeks)
- Bilateral renal artery stenosis or stenosis in a single functioning kidney
- Severe hepatic impairment (Child-Pugh C) — particularly for prodrug ARBs
- Hyperkalaemia >5.5 mmol/L at baseline
- Concurrent use of sacubitril/valsartan (Entresto) — 36-hour washout required when switching
- Concurrent aliskiren in diabetes or CKD (ALTITUDE trial harm)
- Concurrent ACE inhibitor — ONTARGET trial harm without benefit
- Hypersensitivity to valsartan
Breastfeeding: avoid in the first weeks after delivery of a premature infant. Long-term use in established breastfeeding is generally considered acceptable given low milk transfer, but alternative antihypertensives (propranolol, nifedipine) are preferred when possible.
Geneesmiddelinteracties
- Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene) — additive hyperkalaemia; monitor closely
- Potassium supplements and salt substitutes — hyperkalaemia risk
- NSAID's — reduce antihypertensive effect and increase AKI risk (particularly the “triple whammy”: ARB + diuretic + NSAID)
- Lithium — ARBs reduce lithium clearance; monitor levels
- ACE-remmers — do NOT combine (ONTARGET harm)
- Sacubitril/valsartan (Entresto) — do not combine; 36-hour washout
- Aliskiren — avoid in diabetes or CKD (ALTITUDE harm)
ARB Class at a Glance
| ARB | Half-life | Distinguishing niche |
|---|---|---|
| Losartan (Losar, Cosart) | 2 h / 6-9 h (metabolite) | Uricosuric (useful in gout); LIFE trial stroke reduction |
| Olmesartan (Olmin, Olmeheal, Olmesar) | 13 h | Potent per mg; FDA sprue-like enteropathy warning |
| Telmisartan (Telmaheal, Cresar, Targit) | 24 h (longest) | Metabolic benefit (PPAR-γ); ONTARGET CV protection |
| Valsartan (Diovan 160, Valent) | 6 h (24 h effect) | HF evidence (Val-HeFT, VALIANT); ARNI precursor (Entresto) |
| Irbesartan (Irovel) | 11-15 h | Diabetic nephropathy (IRMA-2, IDNT) |
| Candesartan | 9 h | HF evidence (CHARM); not stocked at MedsBase |
ARB vs ACE Inhibitor — When to Choose an ARB
ACE inhibitors (ramipril, enalapril, lisinopril, perindopril) and ARBs act on the same renin-angiotensin pathway and produce equivalent BP-lowering and cardiovascular protection. Choose an ARB when:
- ACE-inhibitor cough has appeared (up to 20% of users; most common reason for switch)
- Past ACE-inhibitor angioedema (use an ARB cautiously, not within 4 weeks of the angioedema episode)
- Some patients prefer the once-daily profile of long-acting ARBs like telmisartan for smooth 24-hour control
- Specific molecule indications — losartan for HTN+gout, irbesartan for type 2 diabetic nephropathy, valsartan as a precursor to ARNI in HF
Do NOT combine ARB + ACE inhibitor. ONTARGET trial (2008) showed the combination produces MORE adverse events (hyperkalaemia, AKI, hypotension) without any additional cardiovascular benefit. If a patient is on both, stop one.
Opslag
Store Valent below 25°C in the original blister pack. Keep out of reach of children.
Veelgestelde vragen
How long does Valent take to lower blood pressure?
Initial BP drop within 1-2 hours; full antihypertensive effect at 3-6 weeks. Measure home BP at the same time each day to track response. If BP has not come to target at 6 weeks, either increase dose or add a second-class agent (CCB or thiazide are the standard add-ons to an ARB).
I switched from an ACE inhibitor because of cough — will my cough go away?
Yes. The ACE-inhibitor cough is caused by bradykinin accumulation; ARBs do not raise bradykinin. The cough typically resolves within 1-4 weeks of stopping the ACE inhibitor. If your cough persists beyond 6 weeks after switching to Valent, investigate an alternative cause (reflux, postnasal drip, asthma).
Can I take Valent in pregnancy?
No — ARBs are absolutely contraindicated in pregnancy, same as ACE inhibitors. They cause fetal renal agenesis, oligohydramnios, pulmonary hypoplasia, and skull defects. Stop immediately if pregnancy occurs. Women of childbearing potential should use reliable contraception; for those planning pregnancy, switch to labetalol, methyldopa, or nifedipine pre-conception.
My creatinine went up a bit after starting Valent — should I stop?
A creatinine rise of up to 30% within the first 1-2 weeks is expected and acceptable. It reflects normal intrarenal haemodynamic adjustment as angiotensin-II-mediated efferent arteriolar tone is removed. A rise >30% suggests bilateral renal artery stenosis, volume depletion, or NSAID interaction and requires investigation (stop the drug, get renal imaging, review concurrent medication).
Should I avoid potassium-rich foods on Valent?
Moderate intake of potassium-rich foods (bananas, oranges, spinach, avocado, potatoes) is fine for most users. Avoid potassium supplements (slow-K) and potassium-containing salt substitutes unless specifically prescribed — these can cause dangerous hyperkalaemia when combined with ARBs, particularly in CKD or with potassium-sparing diuretics.
Can I combine Valent with my other BP medications?
Yes — ARBs combine well with calcium-channel blockers (amlodipine), thiazide diuretics (HCTZ), and beta-blockers (bisoprolol, metoprolol succinate). Do NOT combine an ARB with an ACE inhibitor (ramipril, lisinopril, etc.) — ONTARGET trial showed harm without benefit.
Can I take ibuprofen with Valent?
Occasional short-term use is usually acceptable; chronic daily NSAIDs (ibuprofen, diclofenac, naproxen) reduce the antihypertensive effect of ARBs AND substantially raise the AKI risk — particularly when combined with a diuretic (the “triple whammy”). For chronic pain, paracetamol is safer; for inflammation, discuss alternatives.
Is Valent lifelong?
For most patients with essential hypertension, yes — antihypertensive therapy is lifelong because stopping returns BP to pre-treatment levels within days to weeks. Some patients lose their hypertension through significant weight loss, reduced alcohol intake, or better sleep; their physician may then trial a careful taper under BP monitoring. Never stop Valent without medical advice.
Wat als ik een dosis vergeet?
Take the missed dose as soon as you remember, unless it is nearly time for the next dose — in that case skip the missed dose and continue your normal schedule. Do not double up. A single missed dose will not meaningfully affect long-term BP control.
Where can I buy Valent online?
You can buy Valent (valsartan 80 / 160 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.
Related Antihypertensives on MedsBase
- Cosart-H — Losartan + HCTZ
- Irovel — Irbesartan 150/300 mg
- Lispro — Lisinopril (ACEi alternative)
- Losar — Losartan 25/50 mg
- Olmesar — Olmesartan 20/40 mg
- Targit — Telmisartan 80 mg
- Browse all High Blood Pressure Medications
Gerelateerde alternatieven
Andere producten in Chronische aandoeningen die klanten ook bekijken:
Meer opties in medicatie tegen hoge bloeddruk
Gerangschikt op recente bestelvolumes van MedsBase — wat andere klanten in deze categorie kiezen.
| Sterkte | 80 mg, 160 mg |
|---|---|
| Hoeveelheid | 30 Tabletten, 60 Tabletten, 90 Tabletten, 180 Tabletten |
Valent
Vragen & antwoorden
Valent
Gerelateerde producten
Beoordelingen
Er zijn nog geen beoordelingen